Tarsus Pharmaceuticals/$TARS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Ticker

$TARS
Sector
Primary listing

Employees

323

TARS Metrics

BasicAdvanced
$2.8B
-
-$2.31
0.79
-

What the Analysts think about TARS

Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.

Bulls say / Bears say

Tarsus delivered record net product sales of $102.7 million in Q2 2025, representing a 152% year-over-year increase.
XDEMVY coverage now surpasses 90% of commercial, Medicare, and Medicaid lives, supporting broad patient access.
As of March 31, 2025, Tarsus held about $408 million in cash and cash equivalents following a $135 million public equity offering, reflecting a strong balance sheet.
Tarsus applied a gross-to-net discount of about 47% in Q1 2025, which could put pressure on net revenue margins.
Cost of sales rose to $6.2 million in Q2 2025 from $3.0 million a year ago, reflecting increased manufacturing and royalty expenses.
Research and development expenses climbed to $14.4 million in Q1 2025, up 19% year-over-year, indicating higher investment in the pipeline and increased cash burn.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

TARS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TARS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TARS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs